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Background
Osteoid osteoma is a bone-producing lesion frequently
localized in long bones. The most common presenting
symptom is pain with nocturnal exacerbation, respon-
sive to nonsteroidal anti-inflammatory drugs [1]. Mini-
mally invasive treatment options have become the
standard of care for osteoid osteoma and at present
radiofrequency ablation is the treatment of choice [2].
Only one preliminary study has been performed using
magnetic resonance guided focused ultrasound
(MRgFUS) to treat osteoid osteoma showing MRgFUS
to be effective for pain relief through thermal cell death
and periosteal denervation induced by cortical heating
relative to acoustic energy absorption [3]. The purpose
of this research was to evaluate the efficacy of MRgFUS
in treating osteoid osteoma and to highlight potential
benefits and limitations provided by this technology.
Materials and methods
Seven patients affected by osteoid osteoma were consecu-
tively recruited for MRgFUS (ExAblate 2100, InSightec,
Israel on 1.5 T Signa Twin Speed MR system, GE, USA).
The diagnosis of osteoid osteoma was based on typical
clinical and imaging findings (CT and MRI) . Pain and
function were scored before and after MRgFUS (VAS –
0-10 scale), and any intra- and post-procedure complica-
tion or adverse effect was recorded. Initial follow-up
included clinical assessment at discharge, and every
month.
Results
In one patient the lesion could not be approached due
to the high body mass index (33 Kg/m2). This condition
did not allow a correct positioning of the patient to find
the optimal ultrasound beam window. Six males, ageing
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Table 1 Functional impairment substantially improved in all patients during the first month, and patients’ status
turned to complete restoration of normal function and daily activities. The follow-up is still limited at 3 months.
n°sonication mean energy VASpre VASpost* VASpost** VASpost***
Patient 1 5 1855 J 5 0 0 0
Patient 2 6 1110 J 8 0 0 0
Patient 3 6 1890 J 8 0 0 0
Patient 4 6 1900 J 9 0 0 0
Patient 5 5 535 J 5 0 0 0
Patient 6 8 1650 J 10 5 0 0
* 1 day after the treatment
** 1-month after the treatment
*** 3-month after the treatment
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18-46 years old (mean 26 year-old; BMI 26.2±4.9, range
19.3-34.5 Kg/m2) and presenting with pain scoring 5 to
10 (7.1±2.1) underwent MRgFUS (Figure 2). All osteoid
osteomas were located at femur (head/neck in 4, diaphy-
sis in 2), and in one case the treatment was proposed
for recurrence after being treated by radiofrequency. All
treatments were performed under spinal anesthesia. The
day after the procedure VAS score was 2.3±1.6 (0-5)
(p<0.001), and dropped to 0 in all patients from the 1-
month check onward. Table 1 reports the detailed data for
each patient.
Conclusion
MRgFUS of osteoid osteoma is an extremely promising
treatment. Our first experience confirms its safety and
efficacy. Additional imaging evaluation and an extended
follow-up will be able to support preliminary evidence
and to examine the biological evolution of the bone
lesion.
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